- 英文名称
- Luseogliflozin
- 分子式
- C23H30O6S
- 分子量
- 434.55
- 中文别名
- (2S,3R,4R,5S,6R)-2-(5-(4-乙氧基苄基)-2-甲氧基-4-甲基苯基)-6-(羟甲基)四氢-2H-硫代吡喃-3,4,5-三醇; (2S,3R,4R,5S,6R)-2-[5-[(4-乙氧基苯基)甲基]-2-甲氧基-4-甲基苯基]-6-(羟甲基)噻烷-3,4,5-三醇; 化合物 T21399; 化合物 Luseogliflozin; (2S,3R,4R,5S,6R)-2-(5-(4-Ethoxybenzyl)-2-methoxy-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol; TS-071; Lusefi; (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol; TS-71; TS 071; D-Glucitol, 1,5-dideoxy-1,5-epithio-1-C-[5-[(4-ethoxyphenyl)Methyl]-2-Methoxy-4-Methylphenyl]-, (1S)-; (1S)-1,5-Dideoxy-1,5-epithio-1-C-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-D-glucitol; TS071
- 用途
- 是一种有效的、选择性的、具有口服活性的钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂;作为降糖药物,通过抑制SGLT2减少肾过滤葡萄糖的再吸收和降低尿液中肾糖阈值(RTG)来增加尿葡萄糖的排泄,用于治疗2型糖尿病
